GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS **INSOMNIA AGENTS**

PGST SSB – Ref# 372-D: Edluar, Quviviq, Zolpimist

HPGST SSB – Ref# 406-D: Belsomra, Dayvigo, Edluar, Quviviq, Zolpimist

TGST SSB – Ref# 382-D: Belsomra, Dayvigo, Edluar, Quviviq, Zolpimist

Status: CVS Caremark Criteria
Type: Initial Step Therapy; Post Step Therapy Prior Authorization

INITIAL STEP THERAPY
If the patient has filled a prescription for at least a 30 day supply of at least one generic non-benzodiazepine hypnotic within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA
The requested branded insomnia agent will be covered with post step therapy prior authorization when the following criteria are met:

- The patient has experienced an inadequate treatment response after at least a 30 day trial of at least one generic non-benzodiazepine hypnotic drug
  OR
- The patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic non-benzodiazepine hypnotic drug
  OR
- The patient has experienced an intolerance to at least one generic non-benzodiazepine hypnotic drug

RATIONALE
If the patient has filled a prescription for a least a 30 day supply of at least one generic non-benzodiazepine hypnotic within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried at least one of the generic drugs for at least 30 days and had an inadequate treatment response, then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

REFERENCES
N/A

Written by: UM Development (NB)
Date Written: 04/2009

Revised:	10/2009, 01/2010, 04/2010, 06/2010, 10/2010, 12/2010, 01/2011, 05/2011, 09/2011, 12/2011, 09/2012 (updated formatting and documentation), 10/2012 (removed documentation), 11/2012, 11/2013 (reworded question #2, streamlined order of questions), 04/2014 (removed Lunesta from HPGST & TGST), 08/2014 (removed Lunesta from PGST), 11/2014, 07/2015 (added Belsomra to target list for HPGST & TGST), 08/2015 (added Belsomra to PGST), 11/2015, 04/2016 (removed Intermezzo), 11/2016 (no changes); (SF) 11/2017 (removed Belsomra from PGST), 10/2018 (no changes), 09/2019 (removed Rozerem), 10/2019 (updated with template language), 01/2020 (removed Silenor from HPGST & TGST), 03/2020 (no changes), 03/2021 (no changes), (DFW) 03/2022 (no clinical changes), 11/2022 (Added Quviviq to PGST targeting; Added Dayvigo and Quviviq to HPGST/TGST targeting)
Reviewed:	Medical Affairs (KP) 05/2009, 10/2009, 01/2010, 06/2010, 10/2010, 12/2010, 01/2011, 09/2011, 12/2011; (DC) 09/2012, 11/2012, (LS) 11/2013, (DC) 08/2014, (DC) 11/2014, (CHART) 10/03/2019, (CHART) 10/31/2019, 01/23/2020, (CHART) 03/26/2020, 03/25/2021, 03/31/2022, 12/08/2022
External Review:	05/2009, 12/2009, 02/2010, 04/2010, 08/2010, 02/2011, 08/2011, 01/2012, 04/2013, 04/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019, 10/2019 (FYI), 02/2020, 08/2020, 08/2021 , 08/2022, 12/2022

CRITERIA FOR APPROVAL

1	Has the patient experienced an inadequate treatment response after at least a 30 day trial of at least one generic non-benzodiazepine hypnotic drug? [If yes, then no further questions.]	Yes	No
2	Does the patient have a documented contraindication or a potential drug interaction that would prohibit a trial of at least one generic non-benzodiazepine hypnotic drug? [If yes, then no further questions.]	Yes	No
3	Has the patient experienced an intolerance to at least one generic non-benzodiazepine hypnotic drug?	Yes	No

Mapping Instructions		
	Yes	**No**
1	Approve, 24 months	Go to 2
2	Approve, 24 months	Go to 3
3	Approve, 24 months	Deny